摘要
目的:观察GP方案和GT方案治疗复发转移性乳腺癌疗效及毒副反应。方法:54例复发转移乳腺癌患者随机分为GP组(吉西他滨+顺铂)28例和GT组(吉西他滨+紫杉醇)26例。GP组:吉西他滨800mg～1000mg/m2加入0.9%生理盐水100ml中静滴30分钟,第1天、第8天;顺铂30mg/m^2加入0.9%生理盐水250ml中静滴,第1天～3天,21天重复。GT方案组:吉西他滨800mg～1000mg/m^2加入0.9%生理盐水100ml中静滴30分钟,第1天、第8天;紫杉醇135mg/m^2加入0.9%生理盐水500ml中静滴,第2天,21天重复,2周期后评价疗效。结果:GP方案组有效率46.4%,疾病控制率67.9%,中位生存期11.5月;GT方案组有效率42.3%,疾病控制率69.2%,中位生存期12.6月,两组比较无统计学意义(P>0.05)。主要毒副反应为骨髓抑制、胃肠道反应、脱发。GP组Ⅲ度～Ⅳ度白细胞减少发生率为10.7%,血小板减少发生率为7.1%,贫血发生率为14.3%,恶心呕吐发生率为25.0%,脱发为7.1%。GT组Ⅲ度～Ⅳ度白细胞减少发生率为11.5%,血小板减少发生率为11.5%,贫血发生率为15.4%,恶心呕吐发生率为15.4%,脱发为76.9%。两组毒副反应除脱发显示有统计学意义(P<0.05)外,其余均无统计学意义(P>0.05)。结论:GP和GT方案治疗复发转移性乳腺癌疗效都较好,毒副反应轻,可作为复发转移性乳腺癌的一种化疗方法。
Objective： To compare the efficacy and side effects between GP and GT regimen in the treatment of metastasis beast cancer. Methods： 54 recurrent and metastatic patients diagnosed by pathology were randomly divided into GP group and GT group. Results： The RR（ response rate） of GP group was 46.4% , DCR（ disease control rate） was 67.9%, MST（ median survival time）was 11.5 months. In the GT group, RR was 42. 3%, DCR was 69.2%, MST was 12. 6 months. There was no statistical difference between the two groups （ P 〉 0.05）. The most common toxieities were myelosuppression, gastrointestinal reaction and alopecia. In the GP group , the incidence of grade 3 to 4 leucopenia was 10.7%, grade 3 to 4 thrombocytopenia was 7.1%, grade 3 to 4 nausea and vomiting was 25%, grade 3 to 4 alopecia was 7.1%. In the GT group , the incidence of grade 3 to 4 leucopenia was 11.5%, grade 3 to 4 thrombocytopenia was 11.5% , grade 3 to 4 nausea and vomiting was 15.4% , grade 3 to 4 alopecia was 76.9%. Except the alopecia, there was no statistical difference between the two groups about the side effects. Conclusion： GP and GT regimens are both effective in the treatment of metastasis breast cancer with mild side effects. They both can be chosen for the treatment of metastasis breast cancer.
出处
《肿瘤预防与治疗》
2010年第5期407-409,共3页
Journal of Cancer Control And Treatment
关键词
乳腺癌
复发转移
吉西他滨
化疗
Breast Cancer
Recurrence and Metastasis
Gemcitabine
Chemotherapy
